

## **SIMILAR 10-YEAR SURVIVAL IN BREAST CANCER WITH PATIENTS COMMON BRCA1 MUTATIONS IN POLAND AND LITHUANIA.**

Elsakov P.,<sup>1</sup> Ostapenko V.,<sup>2</sup> Luksyte A.,<sup>2</sup> Smailyte G.<sup>2</sup>

**Key words:** breast cancer, BRCA1 founder mutation, 10-year survival.

of the three BRCA1 mutations - 4153delA, 5382insC and C61G - is a founder mutation in the Polish and Lithuanian populations for breast cancer.

The aim of this study was to estimate the Lithuanian population 10-year survival of a common, with differing prevalence,

BRCA1 (5382insC) founder mutation associated breast cancer patients for comparison with 10-year survival rates in Poland.

The study focused on 263 breast cancer patients (47 patients with strong hereditary cancer criteria and 216 patients unselected

for age or family history) diagnosed in stage (TNM) I-III and treated at Vilnius Oncology Institute between 1996 and 2009.

The results of our study suggested that the 10-year survival rate among breast cancer patients with BRCA1 founder mutations is similar to patients

without a BRCA1 mutation ( $P = 0.7138$ ). The adjusted HR associated with carrying a BRCA1 founder mutation was 1.04 (95% CI, 0.4 to 2.23;  $P > 0.05$ ).

The conclusions of our study are that 10-year survival rates for breast cancer patients are similar in both Poland and Lithuania,

and are not dependent on their BRCA1 common founder mutation contribution or carrier status.